WaVe Life Sciences (WVE) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

WVE · Stock Price

USD 7.24+0.64 (+9.70%)

Market Cap: $1.4B

Historical price data

Market Cap: $1.4BPipeline: 14 drugs (1 Phase 3)Patents: 20Founded: 2010HQ: Singapore, Singapore

Overview

Wave Life Sciences is a clinical-stage biotech focused on developing stereopure oligonucleotide therapeutics via its proprietary PRISM® platform. The company has built a diversified pipeline targeting both rare genetic disorders and common diseases, with key programs in obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006), Duchenne muscular dystrophy, and Huntington's disease. Its strategy combines validated human genetics, a multi-modal RNA-targeting approach, and stereochemistry control to aim for best-in-class efficacy and tolerability. Recent positive interim Phase 1 data in obesity and strategic moves to accelerate its RNA editing portfolio underscore its momentum.

ObesityGenetic DisordersNeuromuscular DiseasesNeurodegenerative Diseases

Technology Platform

PRISM® platform: An integrated system for developing stereopure oligonucleotides, combining proprietary chemistry for single-isomer synthesis with a toolkit of RNA-targeting modalities (RNA editing, splicing modulation, RNAi) and human genetic insights.

Pipeline

14

14 drugs in pipeline1 in Phase 3

Drug	Indication	Stage
WVE-210201 (suvodirsen) + Placebo	Duchenne Muscular Dystrophy	Phase 2/3
WVE-N531	Duchenne Muscular Dystrophy	Phase 2
WVE-N531	Duchenne Muscular Dystrophy	Phase 1/2
WVE-120102 + Placebo	Huntington's Disease	Phase 1/2
SAD: 30mg WVE-003 + SAD: 60mg WVE-003 + SAD: 90mg WVE-003 + ...	Huntington Disease	Phase 1/2

Opportunities

Wave's lead obesity asset, WVE-007, has shown promising early data in a multi-billion dollar market, providing a near-term value catalyst.

Its RNA editing program for AATD (WVE-006) offers first-mover potential in a high-value rare disease space, and the versatile PRISM® platform could generate multiple new candidates.

Risk Factors

Clinical failure in later-stage trials remains the paramount risk, especially against entrenched competitors in obesity.

The novel RNA editing modality is unproven, and the company will require substantial additional capital to reach commercialization, posing dilution risk.

Competitive Landscape

Wave faces intense competition: in obesity from GLP-1 giants and next-gen therapies; in oligonucleotides from leaders like Ionis and Alnylam; and in RNA editing from a growing field of biotechs. Its stereopure chemistry is its key claimed differentiator.

More companies in Singapore →